BioTech IP Review

Recombinant Antibodies and Uses Thereof

Publication No.: WO 2025 058631 A1
Publication Date: March 20, 2025
Filing (Priority) Date: September 17, 2023 (PCT/US2023/032971)
Jurisdiction: International (PCT publication; can enter national phases)
Tech Field: Recombinant antibody therapeutics

What This Patent Application Covers

This patent application describes recombinant antibodies and their uses, including methods for producing and using engineered antibody molecules that bind to specific targets and can be applied therapeutically. − Published application WO2025058631 A1 focuses on engineered immunoglobulin molecules, which could include bispecific or multispecific formats relevant to T‑cell engager modalities (e.g., antibodies that recruit T cells to disease‑associated cells).

Although the published application does not specifically mention “Candid Therapeutics” in the available bibliographic entry, its classification (C07K 16/28: immunoglobulins and related therapeutic formats) and publication timing align with the broader bispecific/multispecific antibody IP landscape underpinning companies like Candid that are developing T‑cell engager drugs.

Why This Is Important

  • Foundational for T‑cell engager drugs: Engineered recombinant antibodies are the core technology behind bispecific and multispecific T‑cell engagers that Candid is advancing in autoimmune disease indications.
  • Commercial leverage: Owning or licensing broad recombinant antibody IP can solidify exclusivity around key drug formats, blocking competitors.
  • Platform relevance: TCEs (bispecific antibodies that bind both a disease target and CD3 on T cells) depend on recombinant antibody engineering. Even pending international applications can be strategically important in biotech valuation and deals.

Instead of having newly granted patents, Candid’s value driver appears to be its therapeutic pipeline and partnering/licensing deals, such as its exclusive global rights to a preclinical trispecific T‑cell engager from WuXi Biologics — a deal with milestone potential up to ~$925 million.

Leave a comment